Physician profile
Sarah Mcclain
NPI 1699162131
$1,961.75
in general payments reported to CMS, 2019-2025
25 companies · $114 in 2025
The $114 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $190 · 2022: $282 · 2023: $414 · 2024: $27.72 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $425.85 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $261.64 | 2019 | |
| Amgen INC. | $258.74 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $157.73 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.66 | 2019-2022 | |
| Abbott Laboratories | $124.64 | 2019 | |
| Corium, LLC | $98.46 | 2022-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $92.12 | 2023 | |
| Upsher-Smith Laboratories LLC | $47.43 | 2020-2022 | |
| Tris Pharma INC | $38.62 | 2019-2022 | |
| Cranial Technologies, INC | $36.12 | 2023-2025 | Doc Band |
| Sanofi Pasteur INC. | $33.89 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $31.26 | 2019-2020 | |
| Gilead Sciences, INC. | $30.99 | 2023 | |
| Merck Sharp & Dohme LLC | $27.24 | 2022-2024 | Vaxneuvance, Gardasil, Capvaxive |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $20.52 | 2023 | Coolseal Generator |
| Neos Therapeutics, LP | $19.84 | 2025 | Adzenys Xr-Odt |
| Azurity Pharmaceuticals, INC. | $17.64 | 2025 | Azmiro |
| Glaxosmithkline, LLC. | $15.29 | 2023 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.77 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.86 | 2023 | Trintellix |
| Shire North American Group INC | $12.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2022 | |
| Amarin Pharma, INC. | $12.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.